Summary (tl;dr)

Vitruvias Therapeutics has issued a nationwide recall for a specific lot of its Thyroid Tablets, USP 30 mg, due to concerns that the medication may be "superpotent" and could cause an overactive thyroid.

Essential Background

Thyroid Tablets, USP are medications derived from porcine thyroid glands, composed of levothyroxine and liothyronine, and are prescribed to treat hypothyroidism, a condition characterized by an underactive thyroid gland. Maintaining precise hormone levels with this medication is crucial for patient health.

The Full Story

Vitruvias Therapeutics Inc. has announced a voluntary nationwide recall of one specific lot (Lot. No. 504950) of its Thyroid Tablets, USP 30 mg. The recall was initiated because laboratory testing confirmed the potential for this lot to be "superpotent," meaning the tablets may contain higher than intended levels of the active thyroid hormones. This affected lot was distributed to wholesalers across the United States between January 31, 2025, and September 30, 2025. While Vitruvias Therapeutics has not yet received any reports of adverse reactions, consumers who are currently taking medication from the recalled lot are advised to consult their healthcare provider for guidance and a potential replacement prescription, rather than discontinuing use independently.

Why It Matters

The superpotency of thyroid medication is a significant concern because it can lead to hyperthyroidism, or an overactive thyroid. Symptoms of hyperthyroidism can include weight loss, heat intolerance, fatigue, nervousness, muscle weakness, hypertension, chest pain, rapid heart rate, and heart rhythm disturbances. The elderly, pregnant women, and infants are particularly at risk, as excess thyroid hormone levels can lead to severe health complications such as cardiac issues in older adults, and maternal and fetal complications (including premature delivery and low birth weight) in pregnant women. In infants, overtreatment could negatively affect growth and development. This recall underscores the critical importance of accurate medication dosing and robust quality control in pharmaceutical manufacturing.

Geographic Location

• Auburn, Lee County, Alabama, United States (Vitruvias Therapeutics headquarters, recall announcement origin)
• United States (nationwide distribution of recalled product)